Article Details
Retrieved on: 2025-01-14 17:12:07
Tags for this article:
Click the tags to see associated articles and topics
Summary
Adaptive Biotechnologies and NeoGenomics have partnered to enhance minimal residual disease monitoring in leukemia through Adaptive's clonoSEQ and NeoGenomics' assessment services. This collaboration leverages biotech innovations in oncology to improve cancer management.
Article found on: www.rttnews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here